Breast Cancer Chemosensitivity Testing via Stromal Cell Isolation
Solution Overview
Problem
Current chemotherapy protocols for breast cancer are limited by drug resistance, leading to suboptimal clinical responses and high recurrence rates, as existing methods for predicting chemotherapy effectiveness are biased by the presence of non-tumor stromal cells in tumor cultures.
Innovation Solution
A method for testing drug candidates using a specific cell culture medium that inhibits stromal cell growth while promoting tumor cell proliferation, allowing for the determination of optimal chemotherapy regimens by culturing breast cancer cells with a defined medium containing growth factors like hydrocortisone, tri-iodo-thyronine, insulin, transferrin, and 17β-Estradiol, and subsequent exposure to drug candidates to assess anti-proliferative activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional culture media are used to culture tumor cells, then both tumor cells and stromal cells grow together, but the presence of stromal cells biases the results of chemosensitivity analysis
Solution Approach 1:
The patent extracts and removes stromal cells from the culture by using a specialized medium that selectively inhibits their growth while allowing tumor cells to proliferate. This separation eliminates the harmful interference of stromal cells in chemosensitivity testing, directly resolving the contradiction between measurement accuracy and stromal cell presence.
Solution Approach 2:
The culture medium is designed with specific local properties - it contains components that create a selective environment where tumor cells thrive while stromal cells are suppressed. This localized quality differentiation within the culture system enables precise chemosensitivity measurement without stromal interference.
2Reliability
If traditional chemotherapy protocols are used, then treatment can be administered immediately, but drug resistance leads to suboptimal clinical response and high recurrence rates
Solution Approach 1:
The patent performs preliminary chemosensitivity testing in vitro before administering chemotherapy in vivo. By culturing tumor cells and exposing them to different drugs beforehand, the optimal treatment regimen is determined in advance, improving therapeutic effectiveness while the one-week testing period represents an acceptable time investment.
3Productivity
If previous ex-vivo testing methods from the early 1990s were used, then drug effectiveness could be predicted, but the results were not sufficiently efficient to justify systematization
Solution Approach 1:
The patent fundamentally changes the cultural parameters of the testing system by using a specialized medium formulation that selectively supports tumor cell growth while inhibiting stromal cells. This parameter change transforms the testing methodology, achieving both high productivity and accurate measurement, thereby justifying systematization of the approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the prediction of chemotherapy effectiveness in less than 10 days, achieving a significant reduction in tumor cell numbers and ensuring reproducibility, thereby improving therapeutic responses and patient survival by isolating tumor cells from stromal influences.
Implementation Method 1
a culture medium allowing the conservation and growth of tumor cells to the detriment of stromal cells
Data Source
Figure 1~2
Figure 3~4
AI summary
Method for ex vivo testing of the effects of (candidate) pharmaceuticals for treatment of breast cancer. Method for ex vivo testing of the effects of (candidate) pharmaceuticals for treatment of breast cancer comprises: (A) culturing cancer cells from a breast sample in a basal medium that contains the following growth factors/ingredients: hydrocortisone (HC) 0.3-0.5 mg/l; triiodothyronine (T3) 0.0004-0.0008 mg/l; insulin 5-15 mg/l; transferrin 4-10 mg/l; recombinant human epidermal growth factor (EGF) 0.05-0.15 mg/l and 17beta -estradiol (E) 0.2-0.3 mg/l, until a culture of cancer cells, essentially free of stromal cells, is produced; (B) contacting the culture with one or more (candidate) pharmaceuticals and (C) identifying, and selecting, one or more of the test compounds that show antiproliferative activity. Independent claims are included for the following: (1) culture medium (CM) that contains growth factors/ingredients specified above; (2) cell culture containing CM and breast cancer cells; and (3) kit for performing the new method comprising CM, transport medium and dissociation medium. ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.
